TY - JOUR
T1 - CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer
AU - Takahara, Naminatsu
AU - Nakai, Yousuke
AU - Isayama, Hiroyuki
AU - Sasaki, Takashi
AU - Saito, Kei
AU - Noguchi, Kensaku
AU - Suzuki, Tatsunori
AU - Nakamura, Tomoka
AU - Sato, Tatsuya
AU - Ishigaki, Kazunaga
AU - Hakuta, Ryunosuke
AU - Takeda, Tsuyoshi
AU - Uchino, Rie
AU - Mizuno, Suguru
AU - Kogure, Hirofumi
AU - Tada, Minoru
AU - Koike, Kazuhiko
N1 - Publisher Copyright:
© 2017, Springer-Verlag GmbH Germany.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Purpose: The role of carbohydrate antigen 19-9 (CA19-9) kinetics in patients with biliary tract cancer (BTC) receiving chemotherapy remains to be elucidated. Methods: A total of 185 advanced or recurrent BTC patients receiving a first line chemotherapy between January 2006 and March 2016, were retrospectively studied. Serum CA19-9 was measured at baseline and after two cycles of chemotherapy, and patients were categorized based on CA19-9 response: CA19-9 decrease group (≥ 30% decrease), stable group (< 30% decrease and < 20% increase) and increase group (≥ 20% increase). The associations of CA19-9 response with radiological tumor response, progression-free survival (PFS) and overall survival (OS) were investigated. Results: There was a statistically significant association between CA19-9 response and radiological tumor responses (p < 0.001). The median PFS and OS were significantly different among three groups according to CA19-9 response: PFS of 8.0, 5.7 and 3.5 months in CA19-9 decrease, stable and increase groups (p < 0.001) and OS of 18.8, 16.0 and 7.5 months in CA19-9 decrease, stable and increase groups, respectively (p < 0.001). Multivariate analyses showed that CA19-9 response was prognostic both of OS and PFS in addition, to CA19-9 at baseline, and performance status. Conclusion: CA19-9 kinetics after the first two cycles of a first line chemotherapy was a prognostic factor for OS and PFS in patients with advanced and recurrent BTC.
AB - Purpose: The role of carbohydrate antigen 19-9 (CA19-9) kinetics in patients with biliary tract cancer (BTC) receiving chemotherapy remains to be elucidated. Methods: A total of 185 advanced or recurrent BTC patients receiving a first line chemotherapy between January 2006 and March 2016, were retrospectively studied. Serum CA19-9 was measured at baseline and after two cycles of chemotherapy, and patients were categorized based on CA19-9 response: CA19-9 decrease group (≥ 30% decrease), stable group (< 30% decrease and < 20% increase) and increase group (≥ 20% increase). The associations of CA19-9 response with radiological tumor response, progression-free survival (PFS) and overall survival (OS) were investigated. Results: There was a statistically significant association between CA19-9 response and radiological tumor responses (p < 0.001). The median PFS and OS were significantly different among three groups according to CA19-9 response: PFS of 8.0, 5.7 and 3.5 months in CA19-9 decrease, stable and increase groups (p < 0.001) and OS of 18.8, 16.0 and 7.5 months in CA19-9 decrease, stable and increase groups, respectively (p < 0.001). Multivariate analyses showed that CA19-9 response was prognostic both of OS and PFS in addition, to CA19-9 at baseline, and performance status. Conclusion: CA19-9 kinetics after the first two cycles of a first line chemotherapy was a prognostic factor for OS and PFS in patients with advanced and recurrent BTC.
KW - Biliary tract cancer
KW - Carbohydrate antigen 19-9
KW - Chemotherapy
KW - Prognostic factors
KW - Retrospective study
UR - http://www.scopus.com/inward/record.url?scp=85031946238&partnerID=8YFLogxK
U2 - 10.1007/s00280-017-3456-9
DO - 10.1007/s00280-017-3456-9
M3 - Article
C2 - 29038848
AN - SCOPUS:85031946238
SN - 0344-5704
VL - 80
SP - 1105
EP - 1112
JO - Cancer Chemotherapy and Pharmacology
JF - Cancer Chemotherapy and Pharmacology
IS - 6
ER -